Key takeaways from webinar:
- Restated goal again of cashflow positive by end of FY24.
- Clear markers on growth, margin, and bottom line set.
- Key cost areas are people, marketing and technology.
- Staff numbers (incl contractors) from 163 -> 169 over the quarter, with some people leaving and others being brought in (commercial).
- Potential for writedowns of acquisitions, subject to outcome of strategic review.
- CEO generally seemed knowledgeable/fluent with business (more so than last webinar) and not scared to address questions directly.
- Group margin 48% for the quarter.
- Re-iterated good capability of underlying architecture and licencing of Novatti - now sits with mgmt team to execute (in perhaps way the business didn't in the past).
- Why do people choose Novatti? (a) Breadth of capability / end-to-end, (b) Make payments a competitive advantage within their customer's businesses.
IBOA responses:
- IBOA has separate Board, CEO, Mgmt etc. Highly independent within the group.
- NOV is 91% shareholder at this point in time, there is a regulatory requirement to reduce this over time.
- It is a difficult time for financing and investment. Despite this, NOV will not be contributing any further funds to the bank.
- Bank Board is actively looking at options to achieve the selldown.
- Vague on whether capital raise required to achieve full licence (spoiler alert - it will be, as need to have signficantly more cash tucked away than they do now).
- CEO seemed supportive of the bank as a cohesive part of the NOV group, making sense as a payments centric and payments focused bank.
AUDD responses:
- Strong believer in thesis that stablecoins will be a stronger part of digital assets moving forwards - supporting customers/businesses that want to move digital assets.
- AUDD has own leadership and management team, who are moving to make stablecoin available to Novatti and customers.
- Mgmt team is looking at a range of funding options to support the growth of AUDD business.
Reckon responses:
- Reckon payments deploying at accelerated pace, but off low base.
I think generally a good wide ranging update
- Forums
- ASX - By Stock
- Ann: Monthly Activities/Appendix 4C Cash Flow Report
Key takeaways from webinar:- Restated goal again of cashflow...
Featured News
Add NOV (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.4¢ |
Change
-0.002(5.56%) |
Mkt cap ! $13.81M |
Open | High | Low | Value | Volume |
3.7¢ | 4.1¢ | 3.4¢ | $187.9K | 4.949M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 127555 | 3.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.5¢ | 150000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 127555 | 0.034 |
4 | 217935 | 0.033 |
8 | 525120 | 0.032 |
8 | 506731 | 0.031 |
10 | 1286467 | 0.030 |
Price($) | Vol. | No. |
---|---|---|
0.035 | 150000 | 1 |
0.036 | 1300000 | 1 |
0.038 | 100000 | 1 |
0.039 | 442439 | 4 |
0.040 | 2343895 | 4 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
NOV (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online